MBOT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Microbot Medical Inc (MBOT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has a unique FDA-cleared product and a positive analyst rating, the financial performance is weak, technical indicators are neutral to bearish, and there are no significant positive catalysts or trading signals supporting immediate action. A hold position is recommended until stronger signals or catalysts emerge.
The technical indicators for MBOT are mixed to bearish. The MACD is negative and contracting, RSI is neutral at 57.444, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels show the stock is trading near its pivot point of 2.624, with resistance at 2.753 and support at 2.495. Pre-market price is up 0.76%, but this is not enough to signal a strong upward trend.
The company has the only FDA-cleared robotic platform for peripheral vascular procedures, which could provide a competitive edge. Analyst coverage initiated with a Buy rating and a $5 price target, citing potential for faster commercial traction.
EPS dropped significantly by -75% YoY. Technical indicators do not show a strong upward trend.
In Q4 2025, revenue remained at $0 with no growth. Net income improved slightly YoY but remains negative at -$3.46M. EPS dropped by -75% YoY to -0.05, indicating worsening profitability. Gross margin remains at 0%.
B. Riley initiated coverage with a Buy rating and a $5 price target, citing the company's unique FDA-cleared product, clinically validated benefits, and a disposable model that bypasses capital equipment procurement. This suggests optimism for long-term growth potential.
